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Abstract:  
More than 130 FDA-approved drugs have been identified for now to prolong the QT interval and possibly lead to sudden 
cardiac death. Due to their toxic effect, some of these drugs have been withdrawn from the pharmaceutical market. In this 
study, we have formulated few rules to assess the ability to prolong QT interval and thereby discriminate between cardio-
toxic and -safe drugs. These rules have clearly determined that cardio-toxic drugs are more likely to obey Lipinski rule of 5 
and Oprea lead-like rule.  Moreover, the cardio-toxic drugs have been found to have in common values of -0.5 to 6.5 log P, 
1-5 nitrogen atoms, up to 4 oxygen atoms, 5-27 hydrophobic atoms, and 15-53 single bonds.  Matthews Correlation 
Coefficient with the value of 0.6 was also attained and nearly 96% of the cardio-toxic drugs were successfully covered.  
Thus, despite the simplicity of this methodology, we have obtained interesting and informative results.  The proposed set of 
these simple rules could be employed to infer cardio-toxicity or -safety for current and potential drugs.  The present study 
will have important impact on decision making in the fields of drug development, molecule screening in biological assays, 
and other applications as well.  
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Background: 
Our thinking and perspective on drug development is now 
being revised due to serious cardiac side effects arising 
from certain drugs available in the market [1-2]. Endorsing 
or banning the process of developing a new drug is now 
more than ever subject to strict scrutiny.  Meanwhile, drug-
related patents and datasets of broader and higher quality 
are accumulating and becoming available in the database 
and as a result, computational approaches are developed in 
parallel aiming to predict cardiac toxicity of such drugs, 
their by-products, and the factors that induce them [3-5]. 
The focus of the current study is to verify certain drugs 
toxicity to the cardiac tissue and thereby differentiate non-
toxic (safe) from toxic drugs. Such drugs lead to QT 
interval prolongation and causes fatal consequences. 
 
Long QT syndrome (LQTS) is usually congenital although 
it can be acquired after administration of certain drugs 
known to affect the heart electrical system, prolong the 
QT-interval and cause a dangerous form of heart 
arrhythmia [6]. QT interval includes both the ventricular 
depolarization and repolarization intervals. Prolongation of 
QT interval induced by drugs is due to increased 
repolarization time through blockade of the outward 
potassium (K
+) current [7].   M o r e  t h a n  8 0 %  Q T -
prolonging drugs have been shown to inhibit the K
+ 
channels encoded by the human ether-a-go-go-related gene 
(hERG) [1-2].  The hERG K
+ channel, a key target for QT-
prolonging drugs, is a voltage-activated channel, expressed 
by multigene family forming tetrameric structure which 
consists of four identical α-subunits  [8].  Each subunit 
consists of six α-helical transmembrane domains. 
Mutations occurred in the hERG localized in the cardiac 
tissue causing loss of channel function leads to congenital 
LQTS [9]. 
 
Cardiac and non-cardiac drugs prolonging QT interval vary 
in their risk or cardiac toxicity [1-2, 10].  The most serious 
risk of such drugs is known by the French term Torsades 
de Pointes (TDP) which also called polymorphic 
ventricular tachycardia, a specific type of dangerous 
ventricular arrhythmia that could deteriorate to fatal 
ventricular fibrillation and results in sudden death.   
Although, some drugs carry a risk of TDP, others are only 
associated with that risk and lack substantial evidences for 
causing TDP. Other types of drugs carry the risk of TDP 
only with patients having congenital LQTS. Many non-
cardiac drugs prolong the QT interval enhancing the risk of 
TDP as a side effect [1, 10].  TDP is usually self-limited 
arrhythmia causing heart shivering, dizziness, or even 
epilepsy and loss of consciousness [11].  TDP can also 
worsen and cause ventricular fibrillation eventfully results 
in sudden death. Drug-induced TDP has been considered 
for the last decade to be the single most common cause of 
the withdrawal
  or restriction of the use of the 
corresponding marketed drugs [12]. The large number of 
non-cardiac drugs that prolong QT interval is rising, 
amongst are antihistamines, anti-psychotics, anti-bacterial, 
and others.  Their potential side effects leading to cardio-
toxicity and resulting in sudden death constitute a major 
concern in drug manufacturing and regulation.  For that 
reason, the focus has been put onto current and potential 
drugs causing QT prolongation in the population [13].  As 
a result, several drugs have been withdrawn from the 
market or restricted in their use, whereas others due to their Bioinformation by Biomedical Informatics Publishing Group                       open access 
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QT prolongation and deadly cardiac consequences were 
not even granted the regulatory approval [12, 10, 14]. 
 
Considering the torsadogenic effect of current drugs and 
due to various measures taken by regulators as to drug 
withdrawal and restriction in the market, our view has been 
that while developing a drug, it is important to test its 
cardio-toxicity using computational tools that employ 
available information on drug structural characteristics.   
These tools could predict cardio-toxicity of a potential drug 
early in its development and thus based on available data 
could verify the LQTS risks saving significant time, labour 
and resources and more importantly avoiding loss of 
patients lives. In this research we have made efforts to 
define a set of counting rules to filter out compounds in 
databases that are not 'cardio-safe'. We have used 
characteristics of known cardio-toxic drugs in terms of 
molecular descriptors and optimized their ranges.  
 
Methodology: 
Learning sets 
A corresponding search in the literature identified several 
drugs that exhibit QT-interval prolonging activity [15-18]. 
Rand Biotechnologies ltd has conducted this search and 
provided us with categories of drugs as follows: 133 
cardio-toxic drugs and 1500 potentially cardio-safe 
marketed drugs. In the current study we aim to develop a 
method that could provide simple rules to be used by 
medicinal chemists for verifying or designing cardio-safe 
molecules.  For such purpose we have utilized 2D-
descriptors which are based on simple whole-molecule 
properties e.g. molecular weight, H-bond donors, H-bond 
acceptors, log P, polar surface area, number of heavy 
atoms, number of hydrophobic atoms, number of rings, 
number of aromatic atoms and bonds, number of carbon, 
nitrogen, oxygen, sulphur and phosphor atoms. 
Descriptors selection and processing 
The decision as to which set of descriptors to be used for 
differentiating between cardio-toxic and -safe drugs is 
crucially important. We sought after the most significant 
set of descriptors from which guidelines for the design of 
safe compounds to be suggested. The selection has been 
performed as following: all descriptors were evaluated 
separately and the best discriminative descriptor was 
chosen to be the core. The second descriptor to be added to 
the core was selected from the rest descriptors while giving 
the best performance in discrimination. The process 
continued until we have five descriptors in the core. 
 
We aim to construct a filter consisting of ranges of 5 
descriptors that can differentiate well between cardio-toxic 
drugs and cardio-safe drugs. For this purpose, ranges of 
descriptors were optimized simultaneously in exhaustive 
search, by maximizing a function (Matthews’ Correlation 
Coefficient, MCC) that considers each of the four possible 
outcomes for any drug – Positive, Negative, False Positive 
and False Negative (equation 1, Supplementary 
material). Higher MCC means better distinction. The 
division process of databases into training set and test set 
has been repeated 5 times with 80% of the cardio-
toxic/cardio-safe drugs, while the remaining (20% of the 
databases) was used as a test set. Each time the division 
was performed by a random choice. The need for a 
combinatorial optimization of descriptors' ranges dictates 
the requirement to transform descriptor values into discrete 
ones. Some descriptors already have a discrete character, 
i.e., the numbers of Nitrogen atoms, H-bond acceptors etc, 
while others, such as molecular weight, polar surface area, 
etc., are continuous. The transformation to discrete 
character was limited to give 50 values for upper and lower 
limit ranges each. 
 
Diversity within drugs induced LQTS
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Figure 1: Diversity within drugs prolonging QT interval. 
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Figure 2: (a-e) Plots of the distribution patterns of number of nitrogen atoms, oxygen atoms, single bonds, hydrophobic 
atoms and log P in the LQTS drugs. 
 
Prediction modelling 
A set of rules is constructed by picking lower limit and 
upper limit for each descriptor. Each set has two values for 
each descriptor, constituting the range which is considered 
to be the “correct” one (by that set of descriptors) for 
cardio-safety. The “correctness” of this set is measured by 
its MCC value, described below. The constructed set of 
rules is applied to the drugs in the training sets to calculate 
the value of the scoring function, its Matthews Correlation 
Coefficient (MCC) (equation 1). An exhaustive search is 
performed for all combinations (around 250 million 
options) and the resulting sets of rules are sorted based on 
their MCC score. The best set of rules is presented. 
 
Discussion: 
We checked the entire diversity within the set of drugs 
inducing QT prolongation and we have found that they are 
very highly diverse (Figure 1). More than 110 compounds 
have Tanimoto index of similarity < 0.7. All cardio-toxic 
drugs were found to obey Lipinski rule of 5 [19] and Oprea 
lead-like rule [20]. Drug-like, according to the Lipinski 
rule of 5, states that orally bio available molecules are 
more likely to have ≤ 5 H-bond donors, ≤ 10 H-bond 
acceptors, ≤ 500 molecular weight and ≤ 5 log P. They 
were derived by an analysis of 2245 drugs. Drug-like 
molecules should have no more than 1 violation – 
descriptor's value that is out of the range. However, lead-
like, according to Oprea, states that lead molecules are 
more likely to have ≤ 450 molecular weight, between -3.5 
and 4.5 log P, ≤ 4 rings, ≤ 10 non-terminal single bonds, ≤ 
5 hydrogen bond donors and ≤ 8 hydrogen bond acceptors. 
They were derived by an analysis of 96 drugs and leads 
from which they were derived. We can obviously see that 
the property criteria for lead-likeness are more stringent 
(inflexible) than that for the Lipinski rule of 5 for drug-
likeness. 
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The data base available  for drugs inducing LQTS was 
utilized for drawing histograms of five discriminative 
descriptors, namely the number of nitrogen and oxygen 
atoms, hydrophobic atoms, single bonds and log P (o/w) 
(Figure 2). These descriptors were employed in this study 
to construct a useful prediction model that is easy for use 
to medicinal chemists in drug design. Histograms' 
construction may help in performing the subsequent 
division of variable values into two sets: a lower range and 
an upper range of each descriptor.  
 
Our LQTS rules states that cardio-toxic drugs are more 
likely to obey Lipinski rule of 5, Oprea lead-like rule as 
well as having: Log P between -0.5 to 6.5, number of 
nitrogen atoms between 1 to 5, number of oxygen atoms is 
up to 4 atoms, number of hydrophobic atoms between 5 to 
27, number of single bonds between 15 to 53. Such 
extracted rules are useful for separating cardio-safe drugs 
from non-safe ones. A Matthews Correlation Coefficient of 
0.6 was attained and nearly 96% of the cardio-toxic drugs 
(true positives) were successfully identified while only 
36% of the cardio-safe drugs (false positives) fall into 
these ranges. These proposed set of rules could be 
employed to infer cardio-toxicity or -safety for current and 
potential drugs. It may have important impact on decision 
making in the fields of drug development, molecule 
screening in biological assays, and other applications as 
well. 
 
Conclusions: 
The molecular characters inherent in the investigated drug 
molecules have shown relevance to cardio-toxicity and -
safety.  Hence, a set of simple rules has been unravelled 
and could become a landmark in the predictive ability 
discriminating between cardio-toxic and – safe drugs.   
Such set of rules maybe widely employed to determine the 
cardio-safety potential of molecules, screening molecules 
for biological assays, as well as for other applications.  
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Supplementary material 
 
Matthews Correlation Coefficient (MCC) equation: 
 
) )( )( )( (
) ( ) (
f f f f
f f
P P N P P N N N
N P PN MCC
+ + + +
− =
                                     (1)  
 
P and N are the percentages of true positive and true negative predictions while Pf and Nf are the percentages of false 
positives and false negatives, respectively. True positives are drugs from a database of cardio-safe drugs that are identified 
as cardio-safe. False positives are cardio-toxic drugs from a cardio-toxic drugs database that are identified as cardio-safe. 
False negatives are cardio-toxic drugs from a cardio-safe drugs database identified as cardio-toxic, and true negatives are 
cardio-toxic drugs from a cardio-toxic drugs’ database, identified as cardio-toxic. The possible values for MCC range 
between -1.0 and 1.0 (1.0 for a perfect prediction and –1.0 for a completely erroneous prediction). 